Interaction of tumour promoters with epithelial cells in culture. An immunofluorescence study.
12-O-tetradecanoyl phorbol-13-acetate (TPA) has a profound and rapid influence on the cytoskeleton of Madin-Darby Canine Kidney (MDCK) cells. Within 10 min, TPA induces a rapid change in morphology, from a flat, cuboidal state to a rounded or elongated morphology in which the cell membranes become convoluted. Concomitant with this morphological change is a rapid dissolution of stress fibres and a redistribution of F-actin from microfilament bundles to a membrane or sub-membranous location. The rearrangement of actin is paralleled by a rearrangement of alpha-actinin and a reduction in the number of vinculin-containing adhesion plaques. Unusual F-actin configurations are often found emanating from a perinuclear location, usually containing alpha-actinin and terminating in a vinculin-containing adhesion plaque. The cytoskeletal rearrangements occur in the presence of inhibitors of protein synthesis or oxidative phosphorylation, but do not occur if glycolysis is also inhibited. The rearrangements are partly abrogated by the presence of cytochalasin B (CB). Despite these dramatic changes in microfilaments the polymerization state of actin remained unaltered after TPA treatment. Furthermore, although changes in the movement of membrane lipids have been reported, no obvious differences in the ability of glycoproteins to redistribute in the plane of the membrane were found as judged by FITC-concanavalin A (conA) induced patching. The rapidity of the morphological response of MDCK cells to TPA indicates that the cytoskeleton is one of the primary targets of TPA, but that tumour promoters differ from RNA tumour viruses in their effect on the state of actin polymerization.
D000185:Actinin / Q000378:metabolism; D000199:Actins / Q000378:metabolism; D000818:Animals; D002273:Carcinogens / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D003208:Concanavalin A / Q000378:metabolism; D003599:Cytoskeleton / Q000187:drug effects*; D004285:Dogs; D004848:Epithelium / Q000187:drug effects / Q000648:ultrastructure*; D005455:Fluorescent Antibody Technique; D007668:Kidney / Q000166:cytology; D008563:Membrane Lipids / Q000378:metabolism; D009124:Muscle Proteins / Q000378:metabolism; D010704:Phorbols / Q000494:pharmacology*; D011975:Receptors, Mitogen / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D016596:Vinculin
D000199:Actins; D002273:Carcinogens; D008563:Membrane Lipids; D009124:Muscle Proteins; D010704:Phorbols; D011975:Receptors, Mitogen; D000185:Actinin; D003208:Concanavalin A; D016596:Vinculin; D013755:Tetradecanoylphorbol Acetate